阿托伐他汀、依折麦布联合依洛尤单抗在急性冠脉综合征患者经皮冠状动脉介入术后的应用价值研究
徐树东 , 贺江波
中国现代医学杂志 ›› 2026, Vol. 36 ›› Issue (17) : 8 -13.
阿托伐他汀、依折麦布联合依洛尤单抗在急性冠脉综合征患者经皮冠状动脉介入术后的应用价值研究
Study on the application value of Atorvastatin, Ezetimibe combined with Evolocumab in ACS patients after PCI
目的 探讨阿托伐他汀、依折麦布联合依洛尤单抗在急性冠脉综合征(ACS)患者经皮冠状动脉介入(PCI)术后的应用价值。 方法 选取2022年3月—2024年3月新疆四七四医院收治的ACS患者,随机分为对照组与观察组,两组均接受PCI治疗,对照组术后服用阿托伐他汀和依折麦布,观察组在对照组的基础上联合注射依洛尤单抗。两组治疗6个月后比较临床疗效、血脂水平、心功能、心肌损伤指标,并记录用药期间不良反应。对患者进行6个月随访,记录主要不良心血管事件(MACE)。 结果 两组各入组62例患者,对照组脱落3例,最终有59例纳入统计分析;观察组脱落5例,最终有57例纳入统计分析;观察组治疗后低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、载脂蛋白B(ApoB)均低于对照组,载脂蛋白A1(ApoA1)高于对照组(P <0.05);观察组治疗前后LDL-C、TC、ApoB、ApoA1的差值均大于对照组(P <0.05)。观察组治疗后脑利钠肽前体(NT-proBNP)、心肌肌钙蛋白 I(cTnI)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)均低于对照组,左室射血分数(LVEF)高于对照组(P <0.05);观察组治疗前后NT-proBNP、cTnI、LVEF、LVEDD、LVESD的差值均大于对照组(P <0.05)。观察组总有效率高于对照组(P <0.05);两组不良反应发生率比较,差异无统计学意义(P >0.05)。观察组MACE发生率低于对照组(P <0.05)。 结论 阿托伐他汀、依折麦布联合依洛尤单抗可提高ACS患者PCI术后的治疗效果,进一步改善血脂代谢和心功能,降低MACE发生风险。
Objective To explore the application value of atorvastatin and ezetimibe combined with evolocumab in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods A total of 124 patients with ACS admitted to Xinjiang 4754 Hospital between March 2022 and March 2024 were randomly divided into an experimental group and a control group (n = 62 each). Both groups underwent PCI. The control group received atorvastatin plus ezetimibe after surgery, and the experimental group additionally received evolocumab. After 6 months, clinical efficacy, lipid metabolism, cardiac function, myocardial injury indicators, adverse reactions, and major adverse cardiovascular events (MACE) were compared. Results After treatment, LDL-C, TC, and ApoB levels were lower and ApoA1 was higher in the experimental group than in the control group; the changes from baseline in LDL-C, TC, ApoB, and ApoA1 were greater in the experimental group (all P < 0.05). After treatment, NT-proBNP, cTnI, LVEDD, and LVESD were lower and LVEF was higher in the experimental group; the changes from baseline in these indicators were also greater in the experimental group (all P < 0.05). The total response rate was higher in the experimental group (P < 0.05). The incidence of adverse reactions did not differ significantly between the groups (P > 0.05), whereas the incidence of MACE was lower in the experimental group (P < 0.05). Conclusion The combination of atorvastatin, ezetimibe and evolocumab can improve the therapeutic effect in patients with ACS after PCI, further optimize lipid metabolism and cardiac function, and reduce the risk of MACE.
| [1] |
Roshdi Dizaji S, Ahmadzadeh K, Zarei H, et al. Performance of Manchester acute coronary syndromes decision rules in acute coronary syndrome: a systematic review and meta-analysis[J]. Eur J Emerg Med, 2024, 31(5): 310-323. |
| [2] |
Losik D, Romanov A, Grazhdankin I, et al. Feasibility of concomitant left atrial appendage closure and percutaneous coronary intervention in patients with acute coronary syndrome and atrial fibrillation: a randomized pilot study[J]. Heart Vessels, 2023, 38(7): 881-888. |
| [3] |
El Houari A, Beladel W, Hilic E, et al. Challenges in the long-term management of stent-related complications: a case of recurrent stent thrombosis and restenosis[J]. Cureus, 2025, 17(7): e88504. |
| [4] |
Zhao Y Q, Zhou Y, Zhou H, et al. Low-density lipoprotein cholesterol, statin therapy, and cerebral microbleeds: The CIRCLE study[J]. Neuroimage Clin, 2023, 39: 103502. |
| [5] |
Khan S, Asif A, Omer O, et al. Statins versus proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors for primary cardiovascular prevention in high-risk patients: a systematic review[J]. Cureus, 2025, 17(5): e83646. |
| [6] |
梁长彬, 周福亮, 贾大林. 阿托伐他汀联合依折麦布对非ST段抬高型急性冠脉综合征患者PCI围手术期Lp-PLA2的影响[J]. 中国医科大学学报, 2024, 53(7): 577-582. |
| [7] |
Lamia T H, Shah-Riar P, Khanam M, et al. Proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors as adjunct therapy to statins: a new frontier in cardiovascular risk reduction[J]. Cureus, 2024, 16(10): e71365. |
| [8] |
中国医师协会急诊医师分会, 国家卫健委能力建设与继续教育中心急诊学专家委员会, 中国医疗保健国际交流促进会急诊急救分会. 急性冠脉综合征急诊快速诊治指南(2019)[J]. 中华急诊医学杂志, 2019, 28(4): 421-428. |
| [9] |
董立均, 武广华. 心血管疾病诊疗指南[M]. 北京: 人民卫生出版社, 1997: 131. |
| [10] |
陈建福, 傅新阳, 林荣富. CYP2C19基因多态性联合血小板功能检测指导抗血小板药物选择对老年ACS患者PCI术后消化道出血的影响分析[J]. 中国临床药理学与治疗学, 2024, 29(9): 1019-1026. |
| [11] |
Kim T O, Lee K, Cho J M, et al. Efficacy and safety of low-dose atorvastatin plus ezetimibe for primary hypercholesterolemia: a randomized, double-blind, multicenter phase 3 trial[J]. Lipids, 2025, 60(5): 317-326. |
| [12] |
Rosenson R S, Tate A, Mar P, et al. Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects[J]. Atherosclerosis, 2024, 392: 117529. |
| [13] |
侯丽君, 刘世杰. ApoE基因多态性对阿利西尤单抗调脂疗效影响的分析[J]. 中国临床药理学杂志, 2024, 40(13): 1851-1854. |
| [14] |
俞佳, 蒋科, 郭莹. 阿利西尤单抗联合阿托伐他汀间歇治疗老年他汀不耐受脑梗死合并高脂血症患者的疗效分析[J]. 中国现代医学杂志, 2024, 34(14): 66-70. |
| [15] |
Almutairi A R, Alshahrani W A, Alhathlol G K, et al. Real-world safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia[J]. Saudi Pharm J, 2024, 32(12): 102203. |
| [16] |
Michaeli D T, Michaeli J C, Boch T, et al. Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with statins compared to statin monotherapy[J]. Clin Drug Investig, 2022, 42(8): 643-656. |
| [17] |
Zheng P, Ding Y Z, Lu F Y, et al. Atorvastatin reverses high cholesterol-induced cardiac remodelling and regulates mitochondrial quality-control in a cholesterol-independent manner: an experimental study[J]. Clin Exp Pharmacol Physiol, 2021, 48(8): 1150-1161. |
| [18] |
王鹤, 郑自强, 姜萍, 多廿烷醇、血脂康联合依折麦布与普伐他汀单药治疗ASCVD高危人群的降脂疗效分析[J]. 中华保健医学杂志, 2026, 28(1): 69-72. |
| [19] |
Tanaka Y, Ikeda T, Ogawa H, et al. Ezetimibe markedly reduces hepatic triglycerides and cholesterol in rats fed on fish oil by increasing the expression of cholesterol efflux transporters[J]. J Pharmacol Exp Ther, 2020, 374(1): 175-183. |
| [20] |
高旭升. 依折麦布联合阿托伐他汀在急性心肌梗死患者PCI术后的应用效果及安全性[J]. 临床合理用药, 2026, 19(4): 48-50. |
| [21] |
Azhar N A A, Chua Y A, Nawawi H, et al. Structural dynamics of LDL receptor interactions with E498A and R499G variants of PCSK9[J]. J Mol Model, 2025, 31(6): 161. |
| [22] |
Hummelgaard S, Vilstrup J P, Gustafsen C, et al. Targeting PCSK9 to tackle cardiovascular disease[J]. Pharmacol Ther, 2023, 249: 108480. |
| [23] |
Chen X M, Liu Y, Zhou Q J, et al. MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes[J]. Front Genet, 2024, 15: 1469094. |
| [24] |
石叶军, 荆玉雷, 李超生, 依洛尤单抗与阿利西尤单抗对缺血性脑卒中的预防作用及用药安全性的Meta分析[J]. 中华神经医学杂志, 2023, 22(7): 673-682. |
新疆维吾尔自治区自然科学基金——青年基金项目(2024D01C288)
/
| 〈 |
|
〉 |